Next Article in Journal
Interaction of a Short Peptide with G-Quadruplex-Forming Sequences: An SRCD and CD Study
Previous Article in Journal
Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments
Previous Article in Special Issue
Pharmacokinetic Comparison between Methotrexate-Loaded Nanoparticles and Nanoemulsions as Hard- and Soft-Type Nanoformulations: A Population Pharmacokinetic Modeling Approach
Review

Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability

by , and *
College of Pharmacy, Gachon University, 191 Hambakmoe-ro, Yeonsu-gu, Incheon 21936, Korea
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Angel Concheiro
Received: 7 June 2021 / Revised: 9 July 2021 / Accepted: 19 July 2021 / Published: 20 July 2021
P-glycoprotein (P-gp) is crucial in the active transport of various substrates with diverse structures out of cells, resulting in poor intestinal permeation and limited bioavailability following oral administration. P-gp inhibitors, including small molecule drugs, natural constituents, and pharmaceutically inert excipients, have been exploited to overcome P-gp efflux and enhance the oral absorption and bioavailability of many P-gp substrates. The co-administration of small molecule P-gp inhibitors with P-gp substrates can result in drug–drug interactions and increased side effects due to the pharmacological activity of these molecules. On the other hand, pharmaceutically inert excipients, including polymers, surfactants, and lipid-based excipients, are safe, pharmaceutically acceptable, and are not absorbed from the gut. Notably, they can be incorporated in pharmaceutical formulations to enhance drug solubility, absorption, and bioavailability due to the formulation itself and the P-gp inhibitory effects of the excipients. Different formulations with inherent P-gp inhibitory activity have been developed. These include micelles, emulsions, liposomes, solid lipid nanoparticles, polymeric nanoparticles, microspheres, dendrimers, and solid dispersions. They can bypass P-gp by different mechanisms related to their properties. In this review, we briefly introduce P-gp and P-gp inhibitors, and we extensively summarize the current development of oral drug delivery systems that can bypass and inhibit P-gp to improve the oral absorption and bioavailability of P-gp substrates. Since many drugs are limited by P-gp-mediated efflux, this review is helpful for designing suitable formulations of P-gp substrates to enhance their oral absorption and bioavailability. View Full-Text
Keywords: P-gp; inhibitors; permeability; drug delivery; solid lipid nanoparticles; micelles; liposomes; polymeric nanoparticles; emulsions P-gp; inhibitors; permeability; drug delivery; solid lipid nanoparticles; micelles; liposomes; polymeric nanoparticles; emulsions
Show Figures

Figure 1

MDPI and ACS Style

Nguyen, T.-T.-L.; Duong, V.-A.; Maeng, H.-J. Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics 2021, 13, 1103. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13071103

AMA Style

Nguyen T-T-L, Duong V-A, Maeng H-J. Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability. Pharmaceutics. 2021; 13(7):1103. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13071103

Chicago/Turabian Style

Nguyen, Thi-Thao-Linh, Van-An Duong, and Han-Joo Maeng. 2021. "Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability" Pharmaceutics 13, no. 7: 1103. https://0-doi-org.brum.beds.ac.uk/10.3390/pharmaceutics13071103

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop